Name
GS1-09 - Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
Date & Time
Tuesday, December 6, 2022
Speakers
Virtual Session Link